Proteome epitope tags and methods of use thereof in protein modification analysis
View Patent ↗Disclosed are methods for reliably detecting the presence of proteins, especially proteins with various post-translational modifications (phosphorylation, glycosylation, methylation, acetylation, etc.) in a sample by the use of one or more capture agents that recognize and interact with recognition sequences uniquely characteristic of a set of proteins (Proteome Epitope Tags, or PETs) in the sample. Arrays comprising these capture agents or PETs are also provided.
1. A method for detecting the presence or absence of a post-translational modification at a location on a target protein within a sample, comprising:
(1) subjecting the target protein to a fragmentation treatment to produce a peptide fragment comprising: (i) at least one potential post-translational modification site; and, (ii) a separate proteome epitope tag (PET) comprising an amino acid sequence unique to the peptide fragment within the sample, wherein the location of the post-translational modification site and the PET within the peptide fragment is known;
(2) contacting the peptide fragment with a capture agent specific for the PET, thereby to bind the peptide fragment at the PET;
(3) contacting the peptide fragment bound to the capture agent specific for the PET with a secondary capture agent specific for the post-translational modification site, wherein the secondary capture agent is labeled with a detectable moiety; and
(4) detecting the secondary capture agent;
wherein detection of the secondary capture agent is indicative of the presence of the post-translational modification at the location within the target protein.
2. The method of claim 1 , further comprising detecting an amount of the peptide fragment bound to the capture agent.
3. The method of claim 2 , further comprising detecting an amount of post-translationally modified residues within the peptide fragment hound to the capture agent.
4. The method of claim 1 , wherein the presence or absence of the post-translational modification is indicative of a disease, a pre-disposition to a disease, or a stage of a disease.
5. The method of claim 3 , wherein the amount of one or more post-translational residues is indicative of a disease, a pre-disposition to a disease, or a stage of a disease.
6. The method of claim 1 , wherein the length of the amino acid sequence is selected from 15-20 amino acids, 20-25 amino acids, 25-30 amino acids, or 30-40 amino acids.
7. The method of claim 1 , wherein the post-translational modification is phosphorylation, and the secondary capture agent is a labeled secondary antibody that recognizes a phosphorylated tyrosine, phosphorylated serine, or phosphorylated threonine.
8. The method of claim 1 , wherein the fragmentation treatment is denaturation and/or fragmentation by a protease, a chemical agent, physical shearing, or sonication.
9. A method for detecting the presence or absence of a post-translational modification at a location on a target protein within a sample, comprising:
(1) subjecting the target protein to a fragmentation treatment to produce a peptide fragment comprising (i) at least one potential post-translational modification site and, (ii) a separate proteome epitope tag (PET) comprising an amino acid sequence unique to the peptide fragment within the sample, wherein the location of the post-translational modification site and the PET within the peptide fragment is known;
(2) contacting the peptide fragment with first and second capture agents respectively specific for the PET and the post-translational modification, one of which is immobilized and the other of which is labeled with a detectable moiety, to bind the fragment at the PET and at the post-translational modification to form a complex; and
(3) detecting, the presence of the detectable moiety in said complex,
wherein detection of the detectable moiety is indicative of the presence of said post-translational modification at the location on the target protein.